These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 19326364)
1. Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. Aagaard L; Thirstrup S; Hansen EH Pharmacoepidemiol Drug Saf; 2009 May; 18(5):401-11. PubMed ID: 19326364 [TBL] [Abstract][Full Text] [Related]
2. [Off-label use of psychotropic medications in pediatric wards: a prospective study]. Winterfeld U; Le Heuzey MF; Acquaviva E; Mouren MC; Brion F; Bourdon O Arch Pediatr; 2009 Sep; 16(9):1252-60. PubMed ID: 19640689 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077 [TBL] [Abstract][Full Text] [Related]
4. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143 [TBL] [Abstract][Full Text] [Related]
5. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial. Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227 [TBL] [Abstract][Full Text] [Related]
7. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014 [TBL] [Abstract][Full Text] [Related]
8. [Hyperactivity and prescription of Ritalin in the canton of Vaud (Switzerland), 2002]. Huissoud T; Jeannin A; Dubois-Arber F Rev Epidemiol Sante Publique; 2007 Oct; 55(5):357-63. PubMed ID: 17889474 [TBL] [Abstract][Full Text] [Related]
9. [Use of methylphenidate among children in Iceland 1989-2006]. Zoëga H; Baldursson G; Halldórsson M Laeknabladid; 2007 Dec; 93(12):825-32. PubMed ID: 18057472 [TBL] [Abstract][Full Text] [Related]
10. Advances in pediatric pharmacology, therapeutics, and toxicology. Berlin CM Adv Pediatr; 2001; 48():439-64. PubMed ID: 11480767 [TBL] [Abstract][Full Text] [Related]
11. The epidemiology of psychotropic drug use in children and adolescents. Bonati M; Clavenna A Int Rev Psychiatry; 2005 Jun; 17(3):181-8. PubMed ID: 16194789 [TBL] [Abstract][Full Text] [Related]
12. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]
13. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386 [TBL] [Abstract][Full Text] [Related]
14. Children in clinical research: a conflict of moral values. Sharav VH Am J Bioeth; 2003; 3(1):W-IF 2. PubMed ID: 14560714 [TBL] [Abstract][Full Text] [Related]
15. The ethics of informed parental consent to psychiatric drugging of children. Breeding J; Baughman F Ethical Hum Sci Serv; 2001; 3(3):175-88. PubMed ID: 15278979 [TBL] [Abstract][Full Text] [Related]
16. Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder. Tucker JD; Suter W; Petibone DM; Thomas RA; Bailey NL; Zhou Y; Zhao Y; Muniz R; Kumar V Mutat Res; 2009; 677(1-2):53-8. PubMed ID: 19465145 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic management of insomnia in children and adolescents: consensus statement. Mindell JA; Emslie G; Blumer J; Genel M; Glaze D; Ivanenko A; Johnson K; Rosen C; Steinberg F; Roth T; Banas B Pediatrics; 2006 Jun; 117(6):e1223-32. PubMed ID: 16740821 [TBL] [Abstract][Full Text] [Related]
18. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/ hyperactivity disorder in children 6 to 17 years of age. Blumer JL; Findling RL; Shih WJ; Soubrane C; Reed MD Pediatrics; 2009 May; 123(5):e770-6. PubMed ID: 19403468 [TBL] [Abstract][Full Text] [Related]
19. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602 [TBL] [Abstract][Full Text] [Related]
20. Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part I. Campbell M; Cueva JE J Am Acad Child Adolesc Psychiatry; 1995 Sep; 34(9):1124-32. PubMed ID: 7559305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]